| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 7.222 | 5.745 | 5.823 | 8.381 | 7.586 | 7.546 | 7.277 | 6.692 | 12.938 | 15.681 |
| Total Income - EUR | 11.571 | 8.311 | 10.310 | 12.637 | 12.490 | 11.849 | 12.298 | 14.268 | 19.326 | 20.057 |
| Total Expenses - EUR | 5.156 | 1.681 | 2.471 | 3.850 | 2.413 | 4.915 | 5.097 | 7.650 | 11.905 | 18.451 |
| Gross Profit/Loss - EUR | 6.415 | 6.630 | 7.838 | 8.787 | 10.078 | 6.934 | 7.201 | 6.618 | 7.421 | 1.607 |
| Net Profit/Loss - EUR | 6.068 | 6.367 | 7.661 | 8.531 | 9.844 | 6.702 | 6.923 | 6.329 | 6.318 | 1.370 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Apomax Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.648 | 2.621 | 2.576 | 14.049 | 33.556 | 32.817 | 32.591 | 32.590 | 31.788 | 31.510 |
| Current Assets | 4.731 | 11.604 | 18.229 | 14.939 | 4.677 | 12.954 | 17.539 | 13.961 | 16.699 | 12.813 |
| Inventories | 364 | 3.894 | 6.290 | 2.590 | 0 | 59 | 58 | 85 | 4.043 | 0 |
| Receivables | 997 | 1.115 | 1.489 | 2.757 | 2.525 | 2.425 | 1.911 | 3.140 | 4.880 | 3.588 |
| Cash | 3.369 | 6.596 | 10.451 | 9.592 | 2.152 | 10.469 | 15.570 | 10.735 | 7.776 | 9.225 |
| Shareholders Funds | 6.838 | 13.136 | 20.449 | 28.605 | 37.895 | 43.879 | 49.829 | 46.174 | 47.298 | 44.383 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 540 | 1.089 | 357 | 383 | 338 | 1.891 | 301 | 378 | 1.189 | -61 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "5630 - 5630" | |||||||||
| CAEN Financial Year |
5630
|
|||||||||
Comments - Apomax Srl